YahooSeptember 8, 2026 at 10:41 AM NYLast Month
Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy
One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key study.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
